Fig. 3From: Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin ESerum TNC levels and the therapeutic effect of omalizumab for patients with severe asthma. Serum TNC levels were significantly higher in the subgroup with an improvement in forced expiratory volume in 1 s (FEV1) of ≥ 12% than that in the subgroup with improvement in FEV1 of < 12%. *P < 0.05Back to article page